

## Editorial

## A Rollercoaster Plunge into 2022

Gregory Y. H. Lip<sup>1,2</sup>  Anne Rigby<sup>3</sup> Christian Weber<sup>3,4,5</sup><sup>1</sup> Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom<sup>2</sup> Department of Clinical Medicine, Aalborg University, Aalborg, Denmark<sup>3</sup> Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany<sup>4</sup> German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany<sup>5</sup> Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands

Address for correspondence Gregory Y. H. Lip, MD, Liverpool Centre for Cardiovascular Science, University of Liverpool, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, United Kingdom (e-mail: gregory.lip@liverpool.ac.uk).

Christian Weber, MD, Institute for Cardiovascular Prevention, LMU Munich, Pettenkoferstrasse 9, 80336 Munich, Germany (e-mail: chweber@med.lmu.de).

Thromb Haemost 2022;122:1–4.

At the same time last year we were very much hoping that the extraordinary research and clinical efforts deployed in response to the pandemic outbreak would mean that we would have stepped out of the rollercoaster wagon this year.<sup>1</sup> But here we are in early 2022: the roller coaster elevating again ready for the next vertical plunge. On this ride, however, we came over unprecedented challenges and worldwide scientific collaboration towards vaccine development was accomplished at a speed and efficiency never imaginable so far. As it became evident thrombosis is playing an intrinsic part of COVID-19, our scientific community naturally fully engaged in this race against the disease. In this New Year Editorial, we reflect back on this rollercoaster year, which 2021 has presented to us all, and project ourselves into the New Year 2022.

As in 2020,<sup>2</sup> we have continued to receive a high proportion of COVID-19-related submissions in 2021, which translated in many COVID-19 publications as reflected in the Editor's Choice published in this issue.<sup>3</sup> As always, we are indebted to our production team as well as our highly reactive reviewers and Editors who have responded to the urgent characteristic of the data and ensured fast track publications without neglecting less urgent but nonetheless fundamental findings.

We are pleased that our impact factor has risen to 5.723 for 2020, meaning *Thrombosis and Haemostasis* (T&H) now ranks 10th out of 65 in the peripheral vascular disease category. Our percentile index in the hematology and peripheral vascular disease category which reflects the impact of T&H in comparison to others in the field has also risen to 85%. We continue to serve as a link journal for the European

Society of Cardiology Working Groups on Thrombosis and on Atherosclerosis and Vascular Biology, as well as being the official journal of the Society of Thrombosis and Haemostasis Research (GTH), the Spanish (SETH) Society on Thrombosis and Haemostasis, and the Australian Vascular Biology Society (AVBS).

## Reviewers

We are very grateful to our near 900 dedicated referees with whom we count on to complete our editorial work thoroughly.

We have to particularly praise our top 10 reviewers for 2021:

- Luis Jara-Palomares
- Erik Klok
- Stefano Barco
- Anetta Undas
- Young-Hoon Jeong
- Daniele Pastori
- Maria Elisa Mancuso
- Hideo Wada
- Shinichi Goto
- Michael Makris

## Section Editors

We have been very lucky to rely on the expertise and dedication from 70 section editors last year. We bid farewell to Daniel Aradi (Hungary), John Eikelboom (Canada), Andras Gruber (United States), Francois Mach (Switzerland), Joao

### received

December 7, 2021

### accepted

December 7, 2021

© 2022. Thieme. All rights reserved.  
Georg Thieme Verlag KG,  
Rüdigerstraße 14,  
70469 Stuttgart, Germany

DOI <https://doi.org/10.1055/s-0041-1741073>.  
ISSN 0340-6245.

Morais (Portugal), and Agneta Siegbahn (Sweden). We thank them for these past years when we have been able to count on their dedicated expertise and look forward to future collaborations and interactions.

We also give a warm welcome to our new colleagues on the Editorial Board: Gemma Vilahur Garcia (Spain) and Surakit Nathisuwan (Thailand), who have joined us as new section editors. We are very pleased that the geographical distribution of our Section Editors is increasingly spanning across the globe (► Fig. 1) and are looking forward to broadening the geographical scope of our Editorial Team further.

A special thank you goes to our last year's 10 most proactive section editors:

- Job Harenberg
- Sam Schulman
- Francesco Violi
- Andreas Greinacher
- Deirdre Lane
- Ramón Lecumberri
- Shinya Goto
- John Eikelboom
- Jeffrey Weitz
- Vera Ignjatovic

## What's New?

### Accepted Manuscript Service Now Available for TH Open

We introduced "Accepted manuscripts" in our last year Editorial.<sup>1</sup> T&H has indeed been pleased to offer authors and readers the possibility to publish and read manuscripts almost upon acceptance. The new scheme has been very welcome as shown by the high numbers of authors who chose it upon submission. We are delighted that this service is now also available for TH Open. Our

readers are therefore able to enjoy reading articles from T&H as well as TH Open in a timely manner, which has proven particularly useful in the current pandemic emergency setting.

### Visual Summaries

In 2020, we introduced optional "Visual Summaries" to convey the main message of the manuscript in a clear and concise graphic manner so that readers can grasp its contents and relevance at a glance. In the past two years, we have received an increasing number of such graphical abstracts which greatly improved the reading quality of the articles published<sup>4-38</sup> some of which have even been selected for the T&H Issue Cover<sup>4,5,11,15,33,38</sup> (► Fig. 2).

We are looking forward to seeing more from these eye catchers, as they will now become mandatory in 2022 and to displaying them in the online Table of Content and social media, to further attract and engage readers with article contents.

### Mini Series

In addition to our traditional Theme Issues, we are excited to introduce two sets of "Mini Series" this year. One of these will consist of "state-of-the-art mini reviews" on a broad range of clinical and basic research topics. We are very grateful for this collaborative effort from our Section Editors who have actively responded to our survey and brought forward timely topics to encapsulate. The other one named "Clinical Concepts in Thrombosis," will encompass short discussions on controversial clinical concept issues by experts in the field. We are very much looking forward to publishing these successively in the coming 2022 issues.

Together with the entire editorial team including Elinor Switzer (Stuttgart), and Thieme Publisher (Stuttgart), we would again like to sincerely thank you, for contributing to the quality of our journal, whether it is by engaging in



**Fig. 1** 2021 geographical distribution of Section Editors at *Thrombosis and Haemostasis*. Map created with Datawrapper.




Fig. 2 Visual summaries, which have made the T&H Cover in 2020 and 2021.

reading or by submitting quality investigations, as well as our section editors and reviewers, for putting their expert skills, reliability, and commitment to the service of T&H.

As always, don't forget to follow us on social media:

Follow us on Social Media!



We are confident that your future contributions will respond to the undoubtedly coming challenges of 2022 and are looking forward to rising to these together.

Conflict of Interest

G.Y.H.L. reports consultancy and speaker fees from Bayer, Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife, Roche, and Daiichi-Sankyo outside the submitted Work. No fees received personally.

References

- 1 Lip GYH, Rigby A, Weber C. Looking Back on 2020, Looking Forward to 2021. *Thromb Haemost* 2021;121(01):1–3
- 2 Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2020 Editors' Choice Papers. *Thromb Haemost* 2021;121(01):109–114
- 3 Weber CRA, Lip GYH. Thrombosis and Haemostasis 2021 Editors' Choice Papers. *Thromb Haemost* 2022;123(01):163–170
- 4 Henning C, Branopolski A, Follert P, et al. Endothelial  $\beta 1$  integrin-mediated adaptation to myocardial ischemia. *Thromb Haemost* 2021;121(06):741–754
- 5 Tian J, Adams MJ, Tay JWT, et al. Estradiol-responsive miR-365a-3p interacts with tissue factor 3'UTR to modulate tissue factor-initiated thrombin generation. *Thromb Haemost* 2021;121(11):1483–1496
- 6 Vilar R, Lukowski SW, Garieri M, Di Sanza C, Neerman-Arbez M, Fish RJ. Chemical modulators of fibrinogen production and their

- impact on venous thrombosis. *Thromb Haemost* 2021;121(04):433–448
- 7 Aliotta A, Bertaggia Calderara D, Zermatten MG, Alberio L. Sodium-calcium exchanger reverse mode sustains dichotomous ion fluxes required for procoagulant COAT platelet formation. *Thromb Haemost* 2021;121(03):309–321
  - 8 Yamashita A, Nishihira K, Gi T, et al. Pathological features of ruptured coronary plaque and thrombus interfaces: fibrin and von Willebrand factor as platelet scaffolds on rupture sites. *Thromb Haemost* 2021;121(02):234–241
  - 9 Billett HH, Reyes-Gil M, Szymanski J, et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. *Thromb Haemost* 2020;120(12):1691–1699
  - 10 de Jong A, Dirven RJ, Boender J, et al. Ex vivo improvement of a von Willebrand disease type 2A phenotype using an allele-specific small-interfering RNA. *Thromb Haemost* 2020;120(11):1569–1579
  - 11 Hsu L-W, Chen P-W, Chang W-T, Lee WH, Liu PY. The role of ROCK in platelet-monocyte collaborative induction of thromboinflammation during acute coronary syndrome. *Thromb Haemost* 2020;120(10):1417–1431
  - 12 Fanikos J, Murwin D, Gruenenfelder F, et al. Global use of idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance program. *Thromb Haemost* 2020;120(01):27–35
  - 13 Akhmedov A, Montecucco F, Costantino S, et al. Cardiomyocyte-specific JunD overexpression increases infarct size following ischemia/reperfusion cardiac injury by downregulating Sirt3. *Thromb Haemost* 2020;120(01):168–180
  - 14 Paterson GG, Young JM, Willson JA, et al. Hypoxia modulates platelet purinergic signalling pathways. *Thromb Haemost* 2020;120(02):253–261
  - 15 Izquierdo I, Barrachina MN, Hermida-Nogueira L, et al. A comprehensive tyrosine phosphoproteomic analysis reveals novel components of the platelet CLEC-2 signaling cascade. *Thromb Haemost* 2020;120(02):262–276
  - 16 Chueh T-H, Cheng Y-H, Chen K-H, Chien CT. Thromboxane A2 synthase and thromboxane receptor deletion reduces ischaemia/reperfusion-evoked inflammation, apoptosis, autophagy and pyroptosis. *Thromb Haemost* 2020;120(02):329–343
  - 17 Tahir S, Wagner AH, Dietzel S, et al. Endothelial CD40 mediates microvascular von Willebrand factor-dependent platelet adhesion inducing inflammatory venothrombosis in ADAMTS13 knockout mice. *Thromb Haemost* 2020;120(03):466–476
  - 18 Wan LM, Zhang SK, Li SB, et al. Heparanase facilitates PMA-induced megakaryocytic differentiation in K562 cells via interleukin 6/STAT3 pathway. *Thromb Haemost* 2020;120(04):647–657
  - 19 Hearn JI, Green TN, Chopra M, et al. N-methyl-D-aspartate receptor hypofunction in Meg-01 cells reveals a role for intracellular calcium homeostasis in balancing megakaryocytic-erythroid differentiation. *Thromb Haemost* 2020;120(04):671–686
  - 20 Smadja DM, Chocron R, Rossi E, et al. Autoregulation of pulsatile bioprosthetic total artificial heart is involved in endothelial homeostasis preservation. *Thromb Haemost* 2020;120(09):1313–1322
  - 21 Gencer S, Lacy M, Atzler D, van der Vorst EPC, Döring Y, Weber C. Immunoinflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19. *Thromb Haemost* 2020;120(12):1629–1641
  - 22 Schulman S, Hu Y, Konstantinides S. Venous thromboembolism in COVID-19. *Thromb Haemost* 2020;120(12):1642–1653
  - 23 Waite AAC, Hamilton DO, Pizzi R, Ageno W, Welters ID. Hypercoagulopathy in severe COVID-19: implications for acute care. *Thromb Haemost* 2020;120(12):1654–1667
  - 24 Polzin A, Dannenberg L, Thienel M, et al. Noncanonical effects of oral thrombin and factor Xa inhibitors in platelet activation and arterial thrombosis. *Thromb Haemost* 2021;121(02):122–130
  - 25 Huang J, Huang S, Ma Z, et al. Ibrutinib suppresses early megakaryopoiesis but enhances proplatelet formation. *Thromb Haemost* 2021;121(02):192–205
  - 26 Potpara TS, Lip GYH, Blomstrom-Lundqvist C, et al. The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): a novel approach to in-depth characterization (rather than classification) of atrial fibrillation. *Thromb Haemost* 2021;121(03):270–278
  - 27 Wayne C, Nguyen T-H, Rollin J, et al. Characterization of new monoclonal PF4-specific antibodies as useful tools for studies on typical and autoimmune heparin-induced thrombocytopenia. *Thromb Haemost* 2021;121(03):322–331
  - 28 Garcia A, Dunoyer-Geindre S, Fish RJ, Neerman-Arbez M, Reny JL, Fontana P. Methods to investigate miRNA function: focus on platelet reactivity. *Thromb Haemost* 2021;121(04):409–421
  - 29 Locke M, Longstaff C. Extracellular histones inhibit fibrinolysis through noncovalent and covalent interactions with fibrin. *Thromb Haemost* 2021;121(04):464–476
  - 30 Basu MK, Massicano F, Yu L, et al. Exome sequencing identifies abnormalities in glycosylation and ANKRD36C in patients with immune-mediated thrombotic thrombocytopenic purpura. *Thromb Haemost* 2021;121(04):506–517
  - 31 Atiq F, van de Wouw J, Sorop O, et al. Endothelial dysfunction, atherosclerosis, and increase of von Willebrand factor and factor VIII: a randomized controlled trial in swine. *Thromb Haemost* 2021;121(05):676–686
  - 32 Schilling U, Dingemans J, Dobrow M, et al. Insights from in vitro and clinical data to guide transition from the Novel P2Y12 antagonist selatogrel to clopidogrel, prasugrel, and ticagrelor. *Thromb Haemost* 2021;121(06):755–766
  - 33 Arroyo AB, Águila S, Fernández-Pérez MP, et al. miR-146a in cardiovascular diseases and sepsis: an additional burden in the inflammatory balance? *Thromb Haemost* 2021;121(09):1138–1150
  - 34 von Hundelshausen P, Lorenz R, Siess W, Weber C. Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors. *Thromb Haemost* 2021;121(11):1395–1399
  - 35 Gissler MC, Scherrer P, Anto-Michel N, et al. Deficiency of endothelial CD40 induces a stable plaque phenotype and limits inflammatory cell recruitment to atherosclerotic lesions in mice. *Thromb Haemost* 2021;121(11):1530–1540
  - 36 Fabris E, Korjian S, Coller BS, et al. Pre-hospital antiplatelet therapy for STEMI patients undergoing primary percutaneous coronary intervention: what we know and what lies ahead. *Thromb Haemost* 2021;121(12):1562–1573
  - 37 Wan J, Konings J, de Laat B, Hackeng TM, Roest M. Added value of blood cells in thrombin generation testing. *Thromb Haemost* 2021;121(12):1574–1587
  - 38 Vaughan CJ, Cronin H, Ryan PM, Caplice NM. Obesity and COVID-19: a Virchow's triad for the 21st century. *Thromb Haemost* 2020;120(11):1590–1593